

28th July 2020

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra East
Mumbai 400 050

Disclosure on impact of the COVID-19 Pandemic

Dear Sirs,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated 20th May 2020, please find below a summary of the impact of the COVID-19 Pandemic on the business and operations of the Company.

#	Particulars	Disclosures
1	Impact of the CoVID-19 pandemic on the business	For the quarter ended 30 th June 2020, the Company has reported a drop in the sales by 5%. Some therapy areas were impacted negatively due to the COVID-19 restrictions. The financial results for the quarter ended 30 th June 2020 are not comparable with that of corresponding quarter in 2019 due to completion of slump sale transaction on 29 th May 2020, which resulted in transfer of Ankleshwar manufacturing facility and few products to Zentiva Private Limited. The continuing operations delivered approx. 1% growth in the quarter ended 30 th June 2020.
2	Ability to maintain operations including the factories/units/ office spaces functioning and closed down	During the quarter ended 30 th June 2020, the Company was able to maintain operations at its manufacturing locations and warehouses to ensure uninterrupted supply of pharma products. The offices of the Company remain to be closed but the employees, including sales employees, continue to work from home on the digital platforms provided by the Company.
3	Schedule, if any, for restarting the operations	The manufacturing and distribution operations are continuing as mentioned in Para 2 above. The decision on opening offices will be taken after the lock down is completely lifted by the state and local governments.

4	Steps taken to ensure smooth functioning of operations	The manufacturing and distribution operations are continuing as mentioned in Para 2 above.
5	Estimation of the future impact of CoVID-19 on its operations	The manufacturing and distribution operations are continuing as mentioned in Para 2 above.
		The impact assessment of COVID-19 is a continuing process given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.
6	Details of impact of CoVID-19 on	
	 capital and financial resources 	None
	 profitability 	Not material
	 liquidity position 	None
	 ability to service debt and other financing arrangements 	Not applicable
	o assets	None
	 internal financial reporting and control 	Not material
	o supply chain	Not material
	 demand for its products / services 	As explained in Para 1 above.
7	Existing contracts/agreements where non-fulfilment of the obligations by any party will have significant impact on the business	Not material
8	Other relevant material updates about the business	None

Please take the same on record.

Thanking you,

Yours sincerely, SANOFI INDIA LIMITED

GIRISH TEKCHANDANI COMPANY SECRETARY